Related Experiment Videos
Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data
Joseph F Dasta1, Sandra L Kane-Gill, Amy J Durtschi
1College of Pharmacy, The Ohio State University, Columbus, OH 43210-1291, USA. Dasta.1@osu.edu
The Annals of Pharmacotherapy
|June 3, 2004
Summary
This study found that while dexmedetomidine (a sedative) is generally used safely in clinical practice, some patients received doses above the maximum or for longer than recommended. Adverse drug reaction rates remained consistent with published data.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Critical Care Medicine
Background:
- New drugs in clinical practice may deviate from recommended labeling.
- Adverse drug reactions (ADRs) often have a delayed reporting period.
- Understanding real-world drug use is crucial for patient safety.
Purpose of the Study:
- To compare the clinical practice prescribing patterns of dexmedetomidine with its product labeling.
- To evaluate the safety and adverse drug reactions (ADRs) of dexmedetomidine in a real-world setting.
- To assess the safety profile of dexmedetomidine against published data.
Main Methods:
- Retrospective data collection from 136 adult patients across 10 institutions.
- Anonymized data on dosing, demographics, and ADRs were collected via a secure online server.
- Medical records were reviewed daily for information on dexmedetomidine administration and patient outcomes.
Main Results:
- Only 33% of patients received a dexmedetomidine loading infusion; maintenance dosing was mostly within guidelines.
- 27.2% exceeded the maximum dose, and 33.8% received the drug longer than 24 hours.
- 30% of patients experienced ADRs, with hypotension being most common (22.7%); rates were similar for prolonged use.
Conclusions:
- Dexmedetomidine use in practice showed deviations from labeling regarding loading doses, maximum dose, and duration of use.
- Despite deviations, the overall rate and type of ADRs were comparable to published reports.
- Dexmedetomidine demonstrated an expected safety profile in clinical practice, even with varied administration patterns.